

## **Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14<sup>th</sup> Monaco Biennale of Oncology 2020**

*The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of cancer*



### **MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, August 29<sup>th</sup>, 2019:**

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announced that it will partner with Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, to host their third annual Innovation Summit and Award in Oncology.

The Lyfebulb-Helsinn Innovation Summit will be held at the Grimaldi Forum in Monaco on January 29<sup>th</sup> and 30<sup>th</sup>, 2020, culminating in the announcement of the 2020 Award winner on January 30<sup>th</sup>, during the 14<sup>th</sup> Monaco Biennale of Oncology.

The Summit is open to Patient Entrepreneurs building groundbreaking companies to advance the prevention, diagnosis, management or care of cancer. Patient Entrepreneurs include cancer patients, cancer survivors, or those having a close relative or loved one with cancer.

All candidates are invited to submit applications through the Lyfebulb-Helsinn Innovation Summit & Award website, where more information regarding eligibility and key criteria is available. Submissions may be made between September 16<sup>th</sup> and November 17<sup>th</sup>, 2019.

**Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented:** “Cancer patients and their real life experience are at the heart of what the Helsinn Group does. We are strongly committed to supporting inspired Patient Entrepreneurs who have a unique insight into products and solutions which can bring respect and integrity to the patient community and quality solutions to the challenges they face.”

“We are thrilled to be partnering with Helsinn again to help accelerate solutions that patients have identified as much needed into the marketplace,” **said Dr Karin Hehenberger, CEO and Founder of Lyfebulb.** “Getting this group of select Patient Entrepreneurs together not only increases their exposure, but also fosters a unique collaboration between innovators with a shared mission of serving patients’ unmet needs.”

### **About the Helsinn Group**

Helsinn is a privately-owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit [www.helsinn.com](http://www.helsinn.com)

### **About Helsinn Investment Fund S.A., SICAR**

The Helsinn Investment Fund is focused on investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.

Drawing on Helsinn's over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.

For more information, visit [www.helsinninvestmentfund.com](http://www.helsinninvestmentfund.com)

### **About Helsinn International Services sarl**

Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.

### **About Lyfebulb**

Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental illness and migraine.

See [www.lyfebulb.com](http://www.lyfebulb.com), [Facebook](#), [Twitter](#), [Instagram](#), [Lyfebulb LinkedIn](#), and [Karin Hehenberger LinkedIn](#).

### ***For more information:***

#### **Helsinn Group Media Contact**

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

[Info-hhc@helsinn.com](mailto:Info-hhc@helsinn.com)

For more information, please visit [www.helsinn.com](http://www.helsinn.com) and follow us on [Twitter](#), [LinkedIn](#) and [Vimeo](#).



**Lyfebulb Media Contact:**

**Karin Hehenberger, MD, PhD**

CEO & Founder, Lyfebulb

Phone: + 1 917-575-0210

Email: [karin@lyfebulb.com](mailto:karin@lyfebulb.com)